Dimension Therapeutics' hemophilia B gene therapy receives FDA fast track designation Sep. 18, 2015 No Comments
Daiichi Sankyo and Translational Sciences to develop thrombus dissolving agent Sep. 17, 2015 No Comments
Andexanet alfa achieves rapid and sustained reversal of rivaroxaban in phase III trial Sep. 16, 2015 No Comments
FDA accepts IND and grants orphan drug designation to DTX-101 for hemophilia B Sep. 14, 2015 No Comments
Akebia reports results from phase II trial of vadadustat in CKD-related anemia Sep. 9, 2015 No Comments
RSS